28 - 1 BMC Musculoskelet Disord 2007 Aug 3;8:73...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Sheet1 Page 1 1. BMC Musculoskelet Disord. 2007 Aug 3 Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. Moore RA, Derry S, McQuay HJ. Pain Research and Nuffield Department of Anaesthetics, University of Oxford, The Churchill, Headington, Oxford, UK. [email protected] BACKGROUND: Differences between gastrointestinal and cardiovascular effects of traditional NSAID or cyclooxygenase-2 selective inhibitor (coxib) are affected by drug, dose, duration, outcome definition, and patient gastrointestinal and cardiovascular risk factors. We calculated the absolute risk for each effect. METHODS: We sought studies with large amounts of information to calculate annualised rates for clearly defined gastrointestinal (complicated upper gastrointestinal perforations, ulcers, or bleeds, but not symptomatic or endoscopic ulcers) and serious cardiovascular outcomes (antiplatelet trial collaborators - APTC - outcome of fatal or nonfatal myocardial infarction or
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.
  • Spring '09
  • ahobaishi
  • Non-steroidal anti-inflammatory drug, Diclofenac, gastrointestinal bleeding, Celecoxib, upper gastrointestinal events

{[ snackBarMessage ]}

Page1 / 2

28 - 1 BMC Musculoskelet Disord 2007 Aug 3;8:73...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online